Novavax Global Commercial Operations and COVID-19 Vaccine Update
Study met co-primary endpoints for homologous
booster indication
Complete Analysis
Neutralizing antibodies
Geometric Mean Titer (GMT)
(95% CI)
Geometric Mean Ratio (GMR)
(95% CI)
Booster
28 Days Post-Boost
4,963
(4,332; 5,687)
Neutralizing antibodies
Seroconversion Rate (SCR)
Booster
28 Days Post-Boost
(95% CI)
Difference in SCR
(95% CI)
3.2
(2.7, 3.8)
Primary Series
14 Days Post-Dose 2
1,542
(1,269; 1,875)
Primary Series
14 Days Post-Dose 2
95.1**
(91.3, 97.5)
92.4*
(88.1, 95.5)
-2.7
(-7.0, 1.3)
Non-inferiority of booster dose vs. Day 35 response for GMFR demonstrated as LB of 95% CI >0.67 and point estimate >0.83, superiority was demonstrated as
LB of 95% CI for GMFR ratio is > 1
Non-inferiority of booster dose vs. Day 35 response for SCRS demonstrated as LB of 95% CI for difference of SCR is > -10%
*Compared to Pre-Boost
novavax:
**Compared to Baseline, Day 0.
Validated wild-type neutralization assays performed at 360BioLabs
© 2023 NOVAVAX. All rights reserved.
31View entire presentation